Baicalein
CAS 491-67-8
Baicalein (CAS 491-67-8) is a Phase 2 pharmaceutical compound with 12 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 20175.890247933887 nM | 120 | - |
| - | Potency | 15733.172897196262 nM | 64 | - |
| - | MIC | 30.7 ug.mL-1 | 32 | - |
| - | EC50 | 13561.675000000001 nM | 28 | - |
| - | AC50 | 12841.995 nM | 6 | - |
| - | IC50 | 18.493333333333332 ug.mL-1 | 6 | - |
| - | Ki | 2272.235 nM | 6 | - |
| - | Kd | 12652 nM | 5 | - |
| - | MIC | 110000 nM | 4 | - |
| - | GI50 | 22400 nM | 3 | - |
| - | EC50 | 100 mg kg-1 | 1 | - |
| - | EC50 | 1.67 ug.mL-1 | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Baicalein used for in pharmaceutical contexts?
Baicalein (CAS 491-67-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Baicalein?
No adverse-event association or SIDER side-effect rows are rendered for Baicalein in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Baicalein also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Baicalein with EU status "permitted".
What clinical phase is Baicalein in?
Baicalein is rendered with ChEMBL max phase 2.